Save Product
Product Details
Synonyms
CEACAM-5, CD66e, CEA, Meconium antigen 100
Source
Human CEACAM-5, His Tag (CE5-H5226) is expressed from human 293 cells (HEK293). It contains AA Lys 35 - Ala 685 (Accession # P06731).
Predicted N-terminus: Lys 35
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 72.2 kDa. The protein migrates as 100-130 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 0.1 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Human CEACAM-5, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
SEC-MALS
The purity of Human CEACAM-5, His Tag (Cat. No. CE5-H5226) is more than 95% and the molecular weight of this protein is around 170-200 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Human CEACAM-5, His Tag (Cat. No. CE5-H5226) at 1 μg/mL (100 μL/well) can bind Anti-CEACAM-5 (labetuzumab) Antibody, Human IgG1 with a linear range of 0.3-5 ng/mL (QC tested).
Protocol
Immobilized Anti-CEACAM-5 (labetuzumab) Antibody, Human IgG1 Antibody at 1 μg/mL (100 μL/well) can bind Human CEACAM-5, His Tag (Cat. No. CE5-H5226) with a linear range of 10-39 ng/mL (Routinely tested).
Protocol
Bioactivity-SPR
Anti-CEACAM-5 (labetuzumab) Antibody, Human IgG1 captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CEACAM-5, His Tag (Cat. No. CE5-H5226) with an affinity constant of 8.41 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Protocol
Customer Reviews Writing Reviews
n***l2026-08-21
LikesThis protein was purchased for target testing. The product was very easy to reconstitute and produced accurate results. The shipping speed of the product was more efficient than estimated which was greatly appreciated. We enjoy ordering high quality products from Acro.
Preguntas Frecuentes
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
Background
Recent Advances
Drug Development Progress- English Name：
Carcinoembryonic antigen related cell adhesion molecule 5
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
18 Details
- Highest Development Stage：
Phase 3 Clinical
Contact Us
Drug Candidate Licensing
